Ireland-based Neurent Medical Ltd has raised $25 million in Series B financing to prepare its lead product for chronic rhinitis for a regulatory application and commercialisation in the US. The product is a medical device to treat symptoms of chronic rhinitis and other inflammatory conditions. The funding round was led by new investor LSP (Life Sciences Partners), from its Health Economics Fund 2, and co-led by Atlantic Bridge. Fountain Healthcare Partners also participated as a returning investor.
